The global tuberculosis
diagnostics market is expected to reach USD 3.1 billion by 2024,
according to a new report by Grand View Research, Inc. Advent of advanced
diagnostic methods such as Interferon-gamma Release Assay (IGRA), serological
methods, and nucleic acid testing have resulted in the high usage rate of
diagnostics. Moreover, Point of Care (POC) technologies such as antigen assays
are also promoting the diagnosis rate of TB.
These advanced methods including POC diagnostics are
affordable, accurate, simple, and yield quick results. Furthermore, the rising
burden of TB is the primary factor responsible for the lucrative market growth.
As per the World Health Organization, the global estimates of patients
afflicted with TB were around 9.6 million in 2014. This high prevalence rate
has led the government, healthcare organizations, research institutes, and
market players to initiate endeavors directed toward containing the incidence
of this infectious disease.
The increasing screening rate in the high burden
regions, affordability of diagnostics, advanced methodologies, faster clinical
decisions, and reduction in mortality rate are the focal areas of development.
Improved preventive and curative diagnosis rates are the end results of these
initiatives. This has led to a subsequent upsurge in the demand for diagnostic
tests and the TB diagnostics market.
Browse full research report on Tuberculosis Diagnostics Market: https://www.grandviewresearch.com/industry-analysis/tuberculosis-diagnostics-market
Further
key findings from the study suggest:
- Based on tests type, the tuberculosis diagnostics market is
segmented into radiographic methods, diagnostic laboratory methods,
nucleic acid testing, phage assay, detection of latent infection, cytokine
detection assay, and detection of drug resistance.
- Diagnostic laboratory tests dominated the test type segment with
38.0% market share in 2015 as they are cost efficient and easy-to-perform.
Diagnostic laboratory tests include smear microscopy and culture-based
tests. The high burden regions rely on these methodologies due to their
financial and technical incapability to incorporate advanced technologies
thus contributing to the growth of the diagnostic laboratory tests
segment.
- However, compromised accuracy and the longer processing time are
the limiting factor for the diagnostics. Hence, healthcare agencies are
striving to implement advanced techniques in the developing regions.
- As a result, nucleic acid tests segment and the latent infection
detection segment, which includes skin tests and IGRA, are likely to
exhibit a profitable growth rate. These methods overcome the
aforementioned limitations thus improving affordability, processing time
and accuracy of the diagnostic method.
- Drug resistance in tuberculosis is one of the primary concerns for
healthcare professionals as improper treatment due to wrong drug regimen
and incorrect dosage forms lead to the development of drug resistance in
TB patients undergoing treatment. Hence, the drug resistance detection
segment is also anticipated to witness lucrative growth.
- Asia Pacific owing to its huge population base and high burden of
TB dominated the global TB diagnostics market in 2015. As per the WHO,
countries such as India, China, Afghanistan, and Indonesia are priority
regions for control of this communicable disease.
- The players in the TB testing market include Thermo Fisher
Scientific, Inc., Hologic Corporation, Abbott Laboratories, Alere, Inc.,
Becton, Dickinson and Company, F. Hoffmann-La Roche AG, bioMérieux SA,
Sanofi, Cepheid, Hain Lifescience GmbH, and QIAGEN.
- New product launches, collaboration, mergers & acquisitions,
and regional expansion are the key strategic initiatives undertaken by
these industry players
- For instance, in July 2016, bioMérieux launched a novel CE marked
database and reagents kit VITEK MS for the identification of TB. This new
product launch is anticipated to help the company increase its market
share.
Browse more reports of this category
by Grand View Research: https://www.grandviewresearch.com/industry/clinical-diagnostics
Grand
View Research has segmented the global tuberculosis diagnostics market on the
basis of test type, and region.
Global
Tuberculosis Diagnostics Test Type Outlook (Revenue, USD Million, 2013 - 2024)
- Radiographic
Method
- Diagnostic
Laboratory Methods
- Smear
Microscopy
- Culture-based
Test
- Nucleic Acid
Testing
- Phage Assay
- Detection of
Latent Infection
- Cytokine
Detection Assay
- Detection of
Drug Resistance
- Other Methods
Tuberculosis
Diagnostics Regional Outlook (Revenue, USD Million, 2013 - 2024)
- North America
- U.S.
- Canada
- Europe
- UK
- Russian
Federation
- Asia Pacific
- China
- India
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
About Grand View
Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment